The KIDnEx2 team will pioneer an inverse drug discovery approach, using electrophilic scout fragments to map the kidney’s ligandable proteome. By pinpointing and validating novel targets, the team will open new paths for potential therapies in cardiorenalmetabolic diseases. Combining advanced proteomics, computational biology, and in vitro models, the team aims to characterize proteins tied to podocyte function and metabolic pathways as potential targets. They will scout fragment library, open datasets, and publications will also lead to an adaptable IDD pipeline for broader impact.
On this page you can follow the project, which will run from 2025-2028.
THE KDInEx2 TEAM
Academic team members
- Markus Rinschen, Assoc. Professor, Aarhus University
- Thomas Poulsen, Professor, Aarhus University
- Amelie Stein, Assoc. Professor, University of Copenhagen
Industrial team member
- Asha Seth, AstraZeneca
- Karolina Nilsson, AstraZeneca
- Michael Christensen, Gubra
- Frederikke Emilie Sembach, Gubra
- Maria Ougaard, Gubra
- Claus Stie Kallesøe, grit42
INDUSTRY PARTNERS IN KIDnEx2
AstraZeneca is global biopharmaceutical company with many different focus areas - kidney diease is just one of them. The head quater of AstraZeneca is based in Sweden.
Grit42 is a Danish company specializing in easy-to-usesoftware available to scientists and projects managers working on pre-clinical drug discovery. As of 5 May 2024, software from Grit42 is available as open source.
Gubra is a CRO and biotech company based in Denmark. It specializes in preclinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases.
Yyou can find out more about the industrial partners in KIDnEx2 using the links below.
"We're excited to join the KIDnEx2 project to explore new mechanisms of action and support innovation in drug discovery within kidney disease. By sharing samples from our advanced mouse model of diabetic kidney disease, we hope to help drive progress in cardiorenal metabolic research.
Gubra works broadly with biotech and big pharma companies across the globe to test new treatments strategies in our well characterized rodent models of kidney disease. By participating in this ODIN project, we aim to help accelerate drug discovery within kidney disease.”
Michael Chrsitensen, Principal Scientist at Gubra
"grit42 recently decided to open source our main scientific data management platform ‘grit’ to make it accessible to both companies and academia.
Our participation in KIDnEx2 is a perfect opportunity for us to validate that we have succeeded in creating a platform that allows researchers to easily manage and share data during and after projects.”
Claus Stie Kallesøe, CEO at grit42
ABOUT ODIN
We unite bright minds from industry and academia to jointly create need-driven clinical research projects - and pave the way for innovative new treatments and diagnostics. We fund the best project ideas through competitive funding calls. Although companies cannot receive funding, it is free of charge to join.
The platform is sponsored by the Novo Nordisk Foundation with 180 million DKK from 2024-2029.
CONTACT ODIN
You are welcome to contact us if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.
Although the platform spans five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 120, blg 1521-214.
